Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors (Q44778139)

6 December 2017

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors (English)

1 reference

6 December 2017

1

Mark S Sulkowski

1 reference

PubMed ID

14986280

6 December 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Clinical Infectious Diseases

6 December 2017

1 reference

6 December 2017

38 Suppl 2

1 reference

6 December 2017

S90-7

1 reference

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

6 December 2017

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir

21 January 2018

1 reference

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

21 January 2018

1 reference

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

21 January 2018

1 reference

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

Antiretroviral drug toxicity -- a challenge for the hepatologist?

21 January 2018

1 reference

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

21 January 2018

HIV-protease inhibitors

1 reference

Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

21 January 2018

1 reference

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

21 January 2018

1 reference

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/381444

1 reference

6 December 2017

1 reference

PubMed ID

14986280